MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
PEG MGF Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
PEG-MGF is a polyethylene-glycol-conjugated form of Mechano Growth Factor (the IGF-1Ec splice variant), engineered to overcome the extraordinarily short systemic half-life of native MGF. PEGylation shields the peptide from renal clearance and proteolysis, extending circulating half-life from minutes to days and permitting systemic subcutaneous dosing rather than the local intramuscular injection required for unmodified MGF. Like native MGF it acts on satellite cells and myoblasts to drive proliferation, recruitment, and tissue repair through a non-canonical receptor distinct from IGF-1R. Researchers study it as a systemic adjunct for muscle recovery, satellite cell pool expansion, and connective-tissue research; it has no FDA approval and is supplied strictly as a research chemical. The peptide is not interchangeable with IGF-1 LR3 or native IGF-1 because the IGF-1Ec E-domain sequence engages a different signalling pathway focused on local satellite cell biology rather than systemic anabolic effects.
Reconstitute: Add 3 mL bacteriostatic water → 0.667 mg/mL concentration.
Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL = 0.0067 mg (7 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Half-life: Approximately 48-72 hours (days, not minutes) thanks to PEGylation; supports systemic SC dosing on a 2-3x weekly schedule unlike the minutes-scale half-life of native MGF.
Mechanism class: Pegylated IGF-1Ec splice variant; engages a non-canonical satellite cell receptor, not IGF-1R, distinguishing it from IGF-1 LR3 and mecasermin.
Versus native MGF: PEGylation allows whole-body distribution and SC dosing; native MGF must be injected intramuscularly at the target site because it clears within minutes.
Stacking: Commonly paired with a GH-axis secretagogue (GHRH + GHRP stack) so that systemic IGF-1 elevation and local satellite cell activation operate in parallel.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Interactive PEG MGF Syringe Calculator
Currently visualizing the 2 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 2mg dry powder in 3mL water yields 0.67 mg/mL. To evaluate a 250mcg dose, pull to 37.5 units (38 syringe ticks).
U-100 Syringe Representation
37.5 Units (38 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg | 30 units (0.30 mL) |
| Weeks 3–4 | 300 mcg | 45 units (0.45 mL) |
| Weeks 5–6 | 400 mcg | 60 units (0.60 mL) |
| Weeks 7–8 | 500 mcg | 75 units (0.75 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 2 mg vial.
Peptide Vials (PEG MGF, 2 mg each):
- check8 weeks ≈ 10 vials
- check12 weeks ≈ 17 vials
- check16 weeks ≈ 24 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- check12 weeks (17 vials): 51 mL → 6 × 10 mL bottles
- check16 weeks (24 vials): 72 mL → 8 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
PEG-MGF retains the 24-amino-acid C-terminal E-domain peptide structure of native MGF, the IGF-1Ec splice product characterised by Yang and Goldspink (FEBS Letters 2002). Pegylation involves covalent attachment of one or more polyethylene glycol chains, typically 20-40 kDa branched mPEG, to lysine residues or the N-terminus of the peptide through stable amide bonds. The PEG shroud serves three pharmacokinetic purposes: it shields proteolytic recognition sites from plasma and tissue proteases, it increases molecular size above the renal filtration cutoff, and it reduces immunogenicity. The functional consequence is that plasma half-life extends from 5-7 minutes for native MGF to approximately 24-48 hours for PEG-MGF, making systemic subcutaneous dosing feasible. PEG-MGF binds the same putative target as native MGF, which appears to be a muscle-specific receptor distinct from the canonical IGF-1R. Engagement drives satellite cell activation, myoblast proliferation, and delayed differentiation, expanding the muscle stem cell pool that contributes to fibre regeneration after damage or overload. The downstream signal involves MAPK and PI3K-Akt pathways shared with IGF-1R signalling, but the upstream receptor selectivity is distinct because pure mature IGF-1 does not reproduce the satellite-cell-expansion phenotype that MGF produces in cell culture. Two key clarifications about PEG-MGF pharmacology: first, the molecule retains the putative receptor selectivity of native MGF and does not activate the IGF-1R/insulin receptor, so it does not produce hypoglycaemia or the body-wide anabolic effects characteristic of IGF-1 LR3. Second, despite the extended half-life, PEG-MGF still requires repeated dosing over weeks to drive measurable satellite cell expansion because the biological pace of myoblast proliferation and fibre regeneration unfolds over days to weeks. Typical research dosing is 100-250 mcg subcutaneously twice per week, often timed post-workout to align with mechanical-overload-induced satellite cell priming. PEG-MGF is sometimes layered onto the canonical CJC-1295/ipamorelin GH secretagogue stack to combine systemic anabolic GH/IGF-1 signal with the satellite-cell-specific MGF signal. There are unresolved methodological concerns from the Matheny et al. (Am J Physiol 2014) work showing no detectable effect of synthetic MGF on primary muscle stem cells, which casts some doubt on the pharmacology that underlies PEG-MGF use; the most defensible interpretation is that endogenous IGF-1Ec splice products operate in a specific tissue-handling context that is not fully recapitulated by exogenous synthetic peptide injection, but research continues to refine this understanding.
Clinical Trial Efficacy Highlights
- starGoldspink (J Anat 1999) characterised the IGF-1Ec splice mechanism as the mechano-transduction signal in skeletal muscle, providing the foundation for MGF and PEG-MGF research.
- starYang and Goldspink (FEBS Lett 2002) demonstrated independent biological activity of the IGF-1Ec E-peptide on myoblast proliferation, distinguishing it from mature IGF-1.
- starHill and Goldspink (J Physiol 2003) showed in rat muscle that IGF-1Ec splice variant transcription preceded IGF-1Ea by hours after mechanical overload, establishing the temporal kinetics of MGF action in muscle repair.
- starKandalla et al. (Mech Ageing Dev 2011) reported that synthetic MGF E-peptide activated human primary myoblasts from elderly donors with enhanced fusion potential, supporting potential applications in sarcopenia research.
- starHameed et al. (J Physiol 2004) demonstrated MGF/IGF-1Ec mRNA was upregulated 100-fold in young men's muscle 2.5 hours after resistance training while older men showed blunted response, mechanistically linking the molecule to age-related sarcopenia.
- starMatheny et al. (Am J Physiol Endocrinol Metab 2014) reported no detectable effect of synthetic MGF E-peptide on primary muscle stem cells, raising methodological concerns about earlier in-vitro findings and the validity of synthetic peptide preparations.
- starDirect PEG-MGF human RCT data do not exist; all human use is research-context observational. Animal models suggest 15-20% cross-sectional area increases with chronic PEG-MGF dosing measured by MRI, but these have not been replicated in controlled human trials.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningInjection-site reactions including erythema, induration and small wheal at the subcutaneous injection site are the most commonly reported research-context adverse effect; the PEG moiety can produce delayed-type reactions in pre-sensitised individuals.
- warningTheoretical immunogenicity from PEG itself: a small subset of users (estimated 1-5%) develop anti-PEG antibodies that can blunt response over time; this is a recognised limitation of all PEG-modified peptides.
- warningMild systemic effects including transient fatigue and warm sensation in the first injections, attributed to the extended half-life increasing systemic exposure compared to native MGF.
- warningNo documented hypoglycaemia because PEG-MGF does not engage the IGF-1R/insulin receptor in the way IGF-1 LR3 does; this is a clinical safety advantage versus the LR3 analogue.
- warningTheoretical concern for accelerated muscle-cell proliferation in the context of pre-existing rhabdomyosarcoma; chronic use contraindicated in patients with muscle malignancy.
- warningNo documented effect on prolactin, cortisol or other endocrine axes because PEG-MGF acts on the putative muscle-specific receptor rather than pituitary or hypothalamic receptors.
- warningLong-term safety beyond 6 months is unstudied; chronic PEG accumulation in tissues has been reported with other pegylated peptides and warrants caution in long-term research protocols.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical PEG-MGF dosage?expand_more
Standard research dosing is 100-250 mcg subcutaneously two times per week, typically timed post-workout to align with mechanical-overload-induced satellite cell priming. The extended 24-48 hour half-life allows twice-weekly dosing rather than the daily or per-workout dosing required for native MGF.
How is PEG-MGF different from MGF?expand_more
Both share the same 24-amino-acid E-domain peptide structure but PEG-MGF carries covalently attached PEG chains that extend plasma half-life from 5-7 minutes to 24-48 hours. PEG-MGF can be administered systemically by subcutaneous injection; native MGF requires local intramuscular injection at the target muscle.
Can PEG-MGF be stacked with other peptides?expand_more
Yes. PEG-MGF is often layered onto the canonical CJC-1295 no DAC / ipamorelin GH secretagogue stack to combine systemic anabolic GH/IGF-1 signal with the satellite-cell-specific MGF signal. The combination is research-context only and human RCT data are absent.
What are the side effects of PEG-MGF?expand_more
Most reported effects are local: injection-site reactions and theoretical PEG-related immunogenicity in pre-sensitised individuals. Unlike IGF-1 LR3, PEG-MGF does not engage the IGF-1R/insulin receptor and does not produce hypoglycaemia or systemic anabolic effects beyond the muscle compartment.
Is PEG-MGF FDA approved?expand_more
No. PEG-MGF has no FDA approval and is supplied solely as a research chemical. It is not on the FDA 503A or 503B bulks lists and is not a recognised therapeutic product in any jurisdiction.
Academic References & Study Citations
Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1-3):156-160. View Scientific Paper →
Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409-418. View Scientific Paper →
Goldspink G. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. J Anat. 1999;194(Pt 3):323-334. View Scientific Paper →
Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano growth factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011;132(4):154-162. View Scientific Paper →
Matheny RW, Geddis AV, Abdalla MN, et al. Mechano-growth factor peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014;306(2):E150-E156. View Scientific Paper →
Hameed M, Lange KH, Andersen JL, et al. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol. 2004;555(Pt 1):231-240. View Scientific Paper →
Philippou A, Maridaki M, Pneumaticos S, Koutsilieris M. The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity. Mol Med. 2014;20(1):202-214. View Scientific Paper →
Brisson BK, Barton ER. New modulators for IGF-I activity within IGF-I processing products. Front Endocrinol. 2013;4:42. View Scientific Paper →
Stavropoulou A, Halapas A, Sourla A, et al. IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med. 2009;15(5-6):127-135. View Scientific Paper →
Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451-1458. View Scientific Paper →